# Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

> **NCT01440595** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 5 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Grazoprevir
- **DRUG:** Placebo to Grazoprevir
- **DRUG:** Peginterferon alfa-2b (Peg-IFN)
- **DRUG:** Ribavirin (RBV)

## Key facts

- **NCT ID:** NCT01440595
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11-28
- **Primary completion:** 2012-05-01
- **Final completion:** 2012-05-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Preliminary results of MK-5172 PN003 (NCT01353911) suggested a possible dose relationship to elevated transaminase levels in treatment with grazoprevir.
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01440595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01440595, "Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01440595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*